Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Sirona Biochem CEO Quarterly Update

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Apr 11, 2022 9:18am

122 Views

Post# 34593163

RE:RE:Sirona Biochem CEO Quarterly Update

Dump the Wanbang bozos.....

Pareto8020 wrote: Why does every update seem to create more confusion and anger for shareholders?

And really - you are hooking up with Wanbang again after they slow walked TFC039 trials until it became a generic in China and worthless?

After all the usual things didn't happen because of things out of thier control.....blah blah blah and then they end it with this cryptic line that hopefully points to a buyout or Linda fnalizing an agreeement.....

"Furthermore, and most importantly: we anticipate very significant positive corporate developments that will completely change the company's financial situation - for the long term."